Skip to main content
Signal8

Dogwood Therapeutics, Inc. (DWTX)

Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Dogwood Therapeutics, Inc. logo

Dogwood Therapeutics, Inc.

NASDAQ:DWTXHealthcare
+3.81%$1.10
Mkt Cap$42.07M
EV$35.7M
Float9.46M
O/S38.23M
VOL82K sh
$ Vol$93K
RVOL0.78×
Inst Own10.5%
SI1.2%
Net Cash/Sh+$0.17
Dilution
Dogwood Therapeutics, Inc. logoNASDAQ:DWTX$1.10+3.81%
Financials Summary
Revenue$0
Net Income-$34.26M
Total Assets$90.17M
Free Cash Flow-$15.62M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$163K
Total Equity$74.9M
Shares Outstanding
Short Interest

No short interest data available.

Split History1 split · 1 reverse
  1. 1:25Reverse split
    Oct 9, 202425 shares → 1
Balance Sheet Details
Assets$90.17M
Liabilities$15.27M
Accounts Receivable$0
Accounts Payable$761K
Inventory$0
PP&E (Net)$195K
Goodwill$12.4M
Intangible Assets$68.99M
Income Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
CurrencyUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$0$0$0$0$0$0$0$0
YoY Growth--------
Cost of Revenue$0$0$0$0$0$0$0$0
Gross Profit$0$0$0$0$0$0$0$0
Gross Margin--------
Research and Development$21.87M$3.53M$1.73M$8.07M$10.8M$194K$801K$854K
Selling, General, and Administrative$6.1M$8.7M$3.72M$4.25M$4.85M$9.81M$1.38M$1.11M
Other$0$0$0$0$0$0$0$0
Total Operating Expenses$27.97M$12.23M$5.45M$12.32M$15.64M$10.01M$2.18M$1.96M
Operating Income (EBIT)-$27.97M-$12.23M-$5.45M-$12.32M-$15.64M-$10.01M-$2.18M-$1.96M
Operating Margin--------
Interest Expense$0$92K$0$0$0$384K$295K$152K
Interest Income$97K$0$151K$67K$6K$0$0$0
Other Income (Expense)-$6.07M-$123K$151K$67K-$319K-$341K-$295K-$152K
Income Before Tax (EBT)-$34.04M-$12.35M-$5.3M-$12.25M-$15.96M-$10.35M-$2.47M-$2.11M
Income Tax Expense$221K-$503$0$0$0$0$0$0
Net Income-$34.26M-$12.35M-$5.3M-$12.25M-$15.96M-$10.35M-$2.47M-$2.11M
Net Income Margin--------
Supplementary Data
EPS-4.32-12.52-7.05-27.66-47.90-52.50-12.80-10.93
Diluted EPS-4.32-12.52-7.05-27.66-47.90-52.50-12.80-10.93
Weighted Average OS8.22M1.03M751,071442,804333,172197,079193,299193,299
EBITDA-$34.03M-$12.25M-$5.3M-$12.25M-$15.96M-$10.01M-$2.18M-$1.96M
EBITDA Margin--------
Balance Sheet
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
CurrencyUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Assets
Current Assets
Cash and Cash Equivalents$6.52M$14.85M$3.32M$7.03M$14.01M$29.8M$309K$30K
Short-Term Investments$0$0$0$0$0$0$0$0
Cash and Short-Term Investments$6.52M$14.85M$3.32M$7.03M$14.01M$29.8M$309K$30K
Accounts Receivable$0$0$0$0$0$324$785$334
Inventory$0$0$0$0$0$0$0$0
Other Current Assets$5K$28K$4K$7K$863$0$0$0
Total Current Assets$8.43M$16.54M$4.17M$8.37M$15.78M$31.47M$316K$42K
Long-Term Assets
Property, Plant & Equipment Net$195K$223K$0$0$0$0$0$0
Goodwill$12.4M$11.81M$0$0$0$0$0$0
Intangible Assets$68.99M$65.71M$0$0$0$0$0$0
Long-Term Investments$0$18K$0$0$0$0$0$0
Deferred Tax Assets$0$0$0$0$0$0$0$0
Other Long-Term Assets$159K$0$0$0$0$0$0$24K
Total Long-Term Assets$81.74M$77.76M$0$0$0$0$0$24K
Other Assets$0$0$0$0$0$0$0$0
Total Assets$90.17M$94.31M$4.17M$8.37M$15.78M$31.47M$316K$66K
Liabilities
Current Liabilities
Accounts Payable$761K$1.23M$112K$573K$354K$369K$35K$146K
Short-Term Debt$0$0$0$0$0$0$0$0
Current Income Tax Payable$0$0$0$0$0$0$0$0
Current Unearned Revenue$0$0$0$0$0$0$0$0
Other Current Liabilities$745K$737K$0$160K$533K$573K$0$0
Total Current Liabilities$3.06M$3.18M$359K$1.04M$1.28M$1.53M$1.62M$1.33M
Long-Term Liabilities
Long-Term Debt$0$15.38M$0$0$0$0$3.64M$0
Long-Term Unearned Revenue$0$0$0$0$0$0$0$0
Long-Term Deferred Tax Liabilities$12.11M$11.31M$0$0$0$0$0$0
Other Long-Term Liabilities$0$0$0$0$0$0$0$0
Total Long-Term Liabilities$12.22M$26.85M$0$0$0$0$3.64M$0
Other Liabilities$0$0$0$0$0$0$0$0
Total Liabilities$15.27M$30.03M$359K$1.04M$1.28M$1.53M$5.26M$1.33M
Stockholders' Equity
Preferred Stock$0$74.41M$0$0$0$0$75K$1.28M
Common Stock$3K$133$77$2K$833$830$12.6M$12.6M
Retained Earnings-$108.08M-$73.82M-$61.47M-$56.17M-$43.93M-$27.97M-$17.62M-$15.15M
Comprehensive Income & Other-$587K-$3.86M$0$0$0$0$0$0
Other Stockholders' Equity$182.97M$138.1M$65.28M$63.5M$58.43M$57.91M$75K$1.28M
Total Equity$74.9M$64.28M$3.81M$7.33M$14.5M$29.94M-$4.94M-$1.26M
Minority Interest$0$0$0$0$0$0$0$0
Total Liabilities and Equity$90.17M$94.31M$4.17M$8.37M$15.78M$31.47M$316K$66K
Supplementary Data
Total Debt$163K$15.59M$0$0$0$0$3.64M$0
Net Debt-$6.36M$738K-$3.32M-$7.03M-$14.01M-$29.8M$3.33M-$30K
Cash Flow Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
CurrencyUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating Activities
Net Income-$34.26M-$12.35M-$5.3M-$12.25M-$15.96M-$10.35M-$2.47M-$2.11M
Depreciation & Amortization$2K$12K$0$0$0$0$0$0
Deferred Income Tax$221K-$503$0$0$0$0$0$0
Stock-Based Compensation$356K$476K$620K$583K$323K$7.43M$0$0
Changes in Working Capital:
  Accounts Receivable$0$0$0$0$0$0$0$0
  Inventory$0$0$0$0$0$0$0$0
  Accounts Payable-$533K$220K-$461K$219K$270K$52K-$90K$66K
  Other Working Capital$400K-$801K$267K-$22K-$322K-$1.03M$406K$803K
Total Working Capital Change-$133K-$581K-$194K$197K-$52K-$974K$316K$869K
Other Non-Cash Items$18.19M$3.65M$0$0$0-$4K$65K$49K
Net Cash from Operating-$15.62M-$8.79M-$4.87M-$11.47M-$15.69M-$3.9M-$2.09M-$1.2M
Investing Activities
Capital Expenditures$0$0$0$0$0$0$0$0
Acquisitions$0$3.76M$0$0$0$0$0$0
Purchases of Investments$0$0$0$0$0$0$0$0
Sales of Investments$0$0$0$0$0$0$0$0
Other Investing Activities$0$0$0$0$0$0$0$0
Net Cash from Investing$0$3.76M$0$0$0$0$0$0
Financing Activities
Debt Repaid-$3M-$15.32M----$1.99M-$2.43M-
Common Stock Issuance$4.34M$1.38M$1.16M$4.49M$0$31.35M$0$0
Common Stock Repurchases$0-$351$0$0-$295K$0$0$0
Dividends Paid$0$0$0$0$0$0$0$0
Other Financing Activities-$54K$0$0$0$198K$113K-$58K-$70K
Net Cash from Financing$7.28M$16.7M$1.16M$4.49M-$98K$33.38M$2.37M$1.15M
Forex Effect$11K-$145K$0$0$0$0$0$0
Net Change in Cash-$8.32M$11.53M-$3.71M-$6.98M-$15.79M$29.49M$279K-$45K
Supplementary Data
Operating Cash Flow-$15.62M-$8.79M-$4.87M-$11.47M-$15.69M-$3.9M-$2.09M-$1.2M
Capital Expenditure$0$5$0-$3$0-$5$0$0
Free Cash Flow-$15.62M-$8.79M-$4.87M-$11.47M-$15.69M-$3.9M-$2.09M-$1.2M
Cash at Beginning$14.85M$3.32M$7.03M$14.01M$29.8M$309K$30K$76K
Cash at End$6.52M$14.85M$3.32M$7.03M$14.01M$29.8M$309K$30K